2022
864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED
INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.Peer-Reviewed Original ResearchGlucose-lowering medicationsPre-specified subgroupsNovartis Pharmaceuticals CorporationGlaxoSmithKline plcDaiichi SankyoDual SGLT1Baseline A1CBaseline eGFRPfizer Inc.Bristol-Myers Squibb CompanyLexicon PharmaceuticalsOutcome trialsCSL BehringNovo NordiskNovartis AGAdvanced chronic kidney diseaseType 2 diabetes patientsEli LillyAmgen Inc.Lower baseline eGFROverall trial populationCKD stage 4Primary composite outcomeSpeakers bureauCardiovascular outcome trials
2019
Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial
Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.Peer-Reviewed Original ResearchPlacebo-controlled trialReduced ejection fractionEffect of dapagliflozinHeart failureFunctional statusSGLT-2iEjection fractionML/min/m2Double-blind placebo-controlled trialCo-primary end pointsDisease-specific health statusHigh-risk patient populationLarge cardiovascular outcome trialsManifest heart failureUrgent HF visitsKey secondary endpointCardiovascular outcome trialsMajority of patientsMin/m2Type 2 diabetesPg/mLExploratory endpointsHF visitsHFrEF patientsSGLT2i dapagliflozin